Show simple item record

dc.contributor.authorSuarez-Giron, Monique C.
dc.contributor.authorCastro-Grattoni, Anabel L.
dc.contributor.authorTorres, Marta
dc.contributor.authorFarré, Ramon
dc.contributor.authorBarbé Illa, Ferran
dc.contributor.authorSánchez de la Torre, Manuel
dc.contributor.authorGozal, David
dc.contributor.authorPicado, Cesar
dc.contributor.authorMontserrat i Capdevila, Josep
dc.contributor.authorAlmendros, Isaac
dc.description.abstractStudy objectives: Chronic intermittent hypoxia (CIH), a hallmark feature of obstructive sleep apnea (OSA), induces accelerated atherogenesis as well as aorta vascular remodeling. Although the cyclooxygenase (COX) pathway has been proposed to contribute to the cardiovascular consequences of OSA, the potential benefits of a widely employed COX-inhibitor such (acetylsalicylic acid, ASA) on CIH-induced vascular pathology are unknown. Therefore, we hypothesized that a common non-selective COX inhibitor such as ASA would attenuate the aortic remodeling induced by CIH in mice. Methods: 40 wild-type C57/BL6malemice were randomly allocated to CIH or normoxic exposures (N) and treated with daily doses of ASA or placebo for 6 weeks. At the end of the experiments, intima-media thickness (IMT), elastin disorganization (ED), elastin fragmentation (EF), length between fragmented fiber endpoints (LFF), aortic wall collagen abundance (AC) and mucoid deposition (MD) were assessed. Results: Compared to N, CIH promoted significant increases in IMT (52.58 ± 2.82μm vs. 46.07 ± 4.18μm, p < 0.003), ED (25.29 ± 14.60% vs. 4.74 ± 5.37%, p < 0.001), EF (5.80 ± 2.04 vs. 3.06 ± 0.58, p < 0.001), LFF (0.65 ± 0.34% vs. 0.14 ± 0.09%, p < 0.001), AC (3.43 ± 1.52% vs. 1.67 ± 0.67%, p < 0.001) and MD (3.40 ± 2.73 μm2 vs. 1.09 ± 0.72 μm2, p < 0.006). ASA treatment mitigated the CIH-induced alterations in IMT: 44.07 ± 2.73μm; ED: 10.57 ± 12.89%; EF: 4.63 ± 0.88; LFF: 0.25 ± 0.17% and AC: 0.90 ± 0.13% (p<0.05 for all comparisons). Conclusions: ASA prevents the CIH-induced aortic vascular remodeling, and should therefore be prospectively evaluated as adjuvant treatment in patients with OSA.ca_ES
dc.description.sponsorshipThis work was supported by the Spanish Respiratory Society (SEPAR), SOCAP, the Associació Lleidatana de Respiratori (ALLER), and the Spanish Fondo de Investigaciones Sanitarias (PI14/00486 and PI14-00004), Instituto de Salud Carlos III (ISCIII), European Regional Development Fund (ERDF) “Una manera de hacer Europa”. DG is supported by National Institutes of Health grant HL130984.ca_ES
dc.publisherFrontiers Mediaca_ES
dc.relation.isformatofReproducció del document publicat a
dc.relation.ispartofFrontiers in Physiology, 2018, vol. 9, núm. 600, p. 1-9ca_ES
dc.rightscc-by (c) Suarez-Giron et al., 2018ca_ES
dc.subjectIntermittent hypoxiaca_ES
dc.subjectSleep apneaca_ES
dc.subjectAcetilsalicilic acidca_ES
dc.titleAcetylsalicylic acid prevents intermittent hypoxia-induced vascular remodeling in a murine model of sleep apneaca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by (c) Suarez-Giron et al., 2018
Except where otherwise noted, this item's license is described as cc-by (c) Suarez-Giron et al., 2018